<DOC>
	<DOCNO>NCT00159224</DOCNO>
	<brief_summary>This study ass safety , tolerability antiviral activity simplify PI-based treatment regimen ( Kaletra , ä ) compare conventional HAART regimens patient infect HIV-1 first boosted-PI antiretroviral treatment regimen . The potency antiviral activity Kaletra clearly demonstrate wide spectrum patient number different clinical trials.6-9 The durable viral suppression see 4 year therapy10 prof provide effective , long-term treatment people HIV-1 . Data one trial ( M97-720 ) ,6 ongoing Phase II study lopinavir/ritonavir combination NRTIs suggest may role monoclass therapy Kaletra treatment HIV-1-infection .</brief_summary>
	<brief_title>Induction-maintenance Lopinavir/r HIV-infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Subject confirm willingness participate study inform aspect trial relevant decision take part , sign date IRB / IEC approve informed consent form . Subject HIV positive first antiretroviral treatment regimen , base two NRTIs plus lopinavir/ritonavir ritonavirboosted PI combination . Subject must previous exposure regimen . Subject viral load &lt; 50 copies/ml time baseline evaluation least 6 month . Subject CD4 cell count ³ 100 cells/mm3 . Subject age &gt; 18 year . Vital sign , physical examination laboratory result exhibit evidence acute illness . Subject treat active opportunistic infection within 30 day screen . If female , subject negative pregnancy test agree use , duration study , barrier method birth control history prove reliability judge investigator . Subject require agrees take , duration study , medication contraindicate antiretroviral drug treatment regimen . The subject agrees take medication , include overthecounter medicine , alcohol , recreational drug without knowledge permission principal investigator Subject current uncontrolled substance abuse psychiatric illness could preclude compliance protocol . Subject viral load &gt; 50 copies/ml Subject HBsAg + Subject active tuberculosis opportunistic infection . Subject active malignancy ( except Kaposi 's Sarcoma ) . Subject liver failure evidence ALT / AST &gt; 5 x Upper Limit Normal ( ULN ) . Female subject pregnant lactating . Subject receive investigational drug within 30 day prior initiation study . Subject modify his/her antiretroviral therapy 3 month prior baseline intend course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Simplification</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV-1 infection</keyword>
</DOC>